Newly Approved
What changed in 2026
Approval applies to the exact product, formulation, population and labeled use.
FDA-approved · July 2026 labelFoundayo (orforglipron)
A once-daily oral GLP-1 receptor agonist approved for long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition, alongside reduced-calorie nutrition and physical activity. It may be taken with or without food. It is not recommended with another GLP-1 medicine.
Important: The label includes a boxed thyroid C-cell tumor warning plus pancreatitis, severe GI, dehydration-related kidney injury, gallbladder, retinopathy, hypersensitivity and anesthesia/aspiration precautions.
Current FDA prescribing information
FDA-approved · March 2026 labelWegovy tablets and 7.2 mg injection
Current Wegovy labeling includes once-daily tablets for eligible adults and a 7.2 mg injection option for certain adults who have tolerated 2.4 mg for at least four weeks and need additional weight reduction. The injection also has a product-specific accelerated-approval MASH indication for eligible adults.
Tablet administration differs from Foundayo: Wegovy tablets are taken on an empty stomach with water, followed by a waiting period before food, drink or other oral medicine.
Current FDA prescribing information
Current label · February 2026Zepbound (tirzepatide)
FDA-approved labeling covers chronic weight management in eligible adults and moderate-to-severe obstructive sleep apnea in adults with obesity. Current labeling must guide dose escalation, contraindications, adverse-effect monitoring and reproductive counseling.
Current FDA prescribing information
